- Home
- GH vs GNTX Comparison
GH vs GNTX Comparison
Compare GH & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- GNTX
- Stock Information
- Founded
- GH 2011
- GNTX 1974
- Country
- GH United States
- GNTX United States
- Employees
- GH N/A
- GNTX N/A
- Industry
- GH Medical Specialities
- GNTX Auto Parts:O.E.M.
- Sector
- GH Health Care
- GNTX Consumer Discretionary
- Exchange
- GH Nasdaq
- GNTX Nasdaq
- Market Cap
- GH 5.5B
- GNTX 4.9B
- IPO Year
- GH 2018
- GNTX N/A
- Fundamental
- Price
- GH $41.72
- GNTX $22.21
- Analyst Decision
- GH Strong Buy
- GNTX Buy
- Analyst Count
- GH 21
- GNTX 7
- Target Price
- GH $52.81
- GNTX $27.50
- AVG Volume (30 Days)
- GH 2.7M
- GNTX 2.1M
- Earning Date
- GH 04-30-2025
- GNTX 04-25-2025
- Dividend Yield
- GH N/A
- GNTX 2.15%
- EPS Growth
- GH N/A
- GNTX N/A
- EPS
- GH N/A
- GNTX 1.72
- Revenue
- GH $773,996,000.00
- GNTX $2,299,862,212.00
- Revenue This Year
- GH $19.53
- GNTX $11.18
- Revenue Next Year
- GH $21.92
- GNTX $7.23
- P/E Ratio
- GH N/A
- GNTX $12.99
- Revenue Growth
- GH 28.20
- GNTX N/A
- 52 Week Low
- GH $18.01
- GNTX $20.28
- 52 Week High
- GH $52.92
- GNTX $35.33
- Technical
- Relative Strength Index (RSI)
- GH 43.79
- GNTX 51.93
- Support Level
- GH $38.86
- GNTX $21.28
- Resistance Level
- GH $52.92
- GNTX $21.99
- Average True Range (ATR)
- GH 2.91
- GNTX 0.58
- MACD
- GH -0.74
- GNTX 0.16
- Stochastic Oscillator
- GH 20.34
- GNTX 66.23
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.